Tranilast (sodium)

• UNSPSC Description:

  Tranilast sodium (MK-341 sodium) acts as an anti-atopic agent. Tranilast suppresses production of prostaglandin D2 (PGD2, IC50= 0.1 mM). Tranilast sodium exhibits anti-inflammatory and immunomodulatory effects[1]. Tranilast sodium antagonizes angiotensin II and inhibits its biological effects in vascular smooth muscle cells[2].

• Target Antigen:

  Angiotensin Receptor; Prostaglandin Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Inflammation/Immunology; Endocrinology; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/tranilast-sodium.html

• Solubility:

  10 mM in H2O

• Smiles:

  O=C([O-])C1=CC=CC=C1NC(/C=C/C2=CC=C(OC)C(OC)=C2)=O.[Na+]

• Molecular Weight:

  349.31

• References & Citations:

  [1]K Ikai , et al. Inhibitory Effect of Tranilast on Prostaglandin D Synthetase. Biochem Pharmacol. 1989 Aug 15;38(16):2673-6.|[2]E A Capper, et al. Modulation of Human Monocyte Activities by Tranilast, SB 252218, a Compound Demonstrating Efficacy in Restenosis. J Pharmacol Exp Ther. 2000 Dec;295(3):1061-9.|[3]Sara Darakhshan, et al. Tranilast Enhances the Anti-Tumor Effects of Tamoxifen on Human Breast Cancer Cells in Vitro. J Biomed Sci. 2013 Oct 21;20(1):76.|[4]M Isaji , et al. Tranilast Inhibits the Proliferation, Chemotaxis and Tube Formation of Human Microvascular Endothelial Cells in Vitro and Angiogenesis in Vivo. Br J Pharmacol. 1997 Nov;122(6):1061-6.|[5]K Miyazawa , et al. Tranilast Antagonizes Angiotensin II and Inhibits Its Biological Effects in Vascular Smooth Muscle Cells. Atherosclerosis. 1996 Apr 5;121(2):167-73.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Launched

• CAS Number:

  104931-56-8